{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:39Z","timestamp":1789505139484,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novartis International AG"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clgc.2014.12.011","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T12:18:01Z","timestamp":1419941881000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Ravindran","family":"Kanesvaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Cohen","family":"Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.12.011_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.12.011_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.011_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.12.011_bib4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.011_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.12.011_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2014.12.011_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1634\/theoncologist.2009-0141","article-title":"Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review","volume":"15","author":"Agarwala","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2014.12.011_bib8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/1535-7163.MCT-06-0071","article-title":"The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling","volume":"5","author":"Ikezoe","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2014.12.011_bib9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1349-7006.2006.00263.x","article-title":"Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase\/Akt\/mammalian target of rapamycin signaling","volume":"97","author":"Ikezoe","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2014.12.011_bib10","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.26429","article-title":"Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma","volume":"118","author":"Molina","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2014.12.011_bib11","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.011_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2014.12.011_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2014.12.011_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-007-0579-4","article-title":"Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety","volume":"62","author":"Guo","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2014.12.011_bib15","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2014.12.011_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.011_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0090-9556(24)15260-9","article-title":"Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats","volume":"27","author":"Crowe","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clgc.2014.12.011_bib18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1023\/A:1011940108365","article-title":"In\u00a0vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin","volume":"15","author":"Crowe","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.clgc.2014.12.011_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-3083.1996.d01-52.x","article-title":"Inhibition by rapamycin of P-glycoprotein 170\u2013mediated export from normal lymphocytes","volume":"43","author":"Yacyshyn","year":"1996","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.clgc.2014.12.011_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9236(01)15633-X","article-title":"Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clgc.2014.12.011_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":"Comparison of the in\u00a0vitro metabolism of the macrolide immunosuppressants sirolimus and RAD","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clgc.2014.12.011_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv170","article-title":"Record-2: A Phase II study of everolimus and bevacizumab vs interferon a-2a and bevacizumab as first line therapy in patients with metastatic RCC","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:45Z","timestamp":1761564345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314002857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1558767314002857"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.12.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}